Published in Br J Cancer on February 01, 2000
Tumour necrosis factor and cancer. Nat Rev Cancer (2009) 6.27
Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest (2002) 1.67
Death receptors as targets in cancer. Br J Pharmacol (2013) 1.24
Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas. Invest New Drugs (2006) 1.00
Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. J Clin Invest (2002) 0.91
Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example. BioDrugs (2013) 0.88
Increased tumor necrosis factor receptor 1 expression in human colorectal adenomas. World J Gastroenterol (2012) 0.85
Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma. Curr Treat Options Oncol (2007) 0.84
Dynamic contrast-enhanced MRI using macromolecular contrast media for monitoring the response to isolated limb perfusion in experimental soft-tissue sarcomas. MAGMA (2004) 0.81
Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions. Br J Cancer (2000) 0.80
Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity. Br J Cancer (2002) 0.78
The diverse roles of the TNF axis in cancer progression and metastasis. Trends Cancer Res (2016) 0.77
Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion. Br J Cancer (2003) 0.77
Recombinant mutated human TNF in combination with chemotherapy for stage IIIB/IV non-small cell lung cancer: a randomized, phase III study. Sci Rep (2015) 0.77
Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow? Gene Ther (2010) 0.76
Lack of efficacy of Doxil in TNF-alpha-based isolated limb perfusion in sarcoma-bearing rats. Br J Cancer (2004) 0.75
Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol (1996) 2.61
Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med (1998) 2.42
High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol (1992) 2.12
Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol (1987) 1.85
Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol (1992) 1.82
Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition, and cytotoxicity. J Natl Cancer Inst (1986) 1.68
Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res (1988) 1.54
Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res (1989) 1.47
Recombinant human tumor necrosis factor-alpha: thrombus formation is a cause of anti-tumor activity. Int J Cancer (1988) 1.19
Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol (1988) 1.10
Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer (1993) 1.10
Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer (1999) 1.06
Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br J Cancer (1996) 1.06
Increased adriamycin levels in hepatic implants of rabbit Vx-2 carcinoma from regional infusion. Cancer Res (1988) 1.02
Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg (1996) 1.00
Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer (1996) 0.99
VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha. J Pathol (1995) 0.98
Distribution of adriamycin in cancer patients: tissue uptakes, plasma concentration after IV and hepatic IA administration. Cancer (1980) 0.97
Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res (1987) 0.97
Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site. Cancer Res (1997) 0.95
Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol (1997) 0.93
Cytotoxics and hyperthermic perfusion: a preliminary study. Cancer Treat Rev (1979) 0.92
Regional therapy of melanoma. Eur J Cancer (1993) 0.92
Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approach. Eur J Surg Oncol (1996) 0.90
Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer (1989) 0.90
Flow cytometric analysis of doxorubicin accumulation in cells from human and rodent cell lines. J Natl Cancer Inst (1989) 0.90
Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res (1994) 0.86
Increased antitumor effect of immunoconjugates and tumor necrosis factor in vivo. Cancer Res (1988) 0.84
Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? Eur J Cancer (1996) 0.84
Augmentation for intratumoral accumulation and anti-tumor activity of liposome-encapsulated adriamycin by tumor necrosis factor-alpha in mice. Int J Cancer (1990) 0.83
Adriamycin in hyperthermic perfusion for advanced limb sarcomas. Ann Oncol (1992) 0.82
Isolated lung perfusion with doxorubicin prolongs survival in a rodent model of pulmonary metastases. Ann Thorac Surg (1997) 0.82
Sensitivity of drug-resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-alpha) and doxorubicin: failure of the combination to modulate the MDR phenotype. Gynecol Oncol (1993) 0.82
Isolated single lung perfusion with doxorubicin is effective in eradicating soft tissue sarcoma lung metastases in a rat model. J Thorac Cardiovasc Surg (1994) 0.82
Assessment of the role of neutrophils on the antitumor effect of TNFalpha in an in vivo isolated limb perfusion model in sarcoma-bearing brown Norway rats. J Surg Res (1998) 0.81
High-flow isolation perfusion of the rat hind limb in vivo. J Surg Oncol (1982) 0.79
Tumor necrosis factor induces doxorubicin resistance to lung cancer cells in vitro. J Thorac Cardiovasc Surg (1994) 0.79
Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells. Gynecol Oncol (1990) 0.78
Effect of tumor necrosis factor on human tumor cell lines sensitive and resistant to cytotoxic drugs, and its interaction with chemotherapeutic agents. Anticancer Drugs (1990) 0.78
Doxorubicin-induced cross-resistance to tumor necrosis factor (TNF) related to differential TNF processing. J Immunother (1991) (1991) 0.78
Palliative chemotherapy of adult soft tissue sarcomas. Semin Oncol (1995) 0.77
Sunscreen use and duration of sun exposure: a double-blind, randomized trial. J Natl Cancer Inst (1999) 3.75
An evaluation of risk factors in incisional hernia recurrence. Surg Gynecol Obstet (1993) 2.63
Indications and long-term outcome of treatment for benign hepatic tumors: a critical appraisal. Arch Surg (2001) 1.95
Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med (1999) 1.67
Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases. Br J Surg (2010) 1.65
Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg (1996) 1.54
Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J Immunol Methods (2000) 1.53
Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model. J Immunother (2000) 1.52
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46
Adjuvant interferon-alpha for melanoma revisited: news from old and new studies. Ann Oncol (2001) 1.43
[Topical corticosteroid injection for 'trigger finger': good short-term results, but fairly high risk of recurrence]. Ned Tijdschr Geneeskd (1998) 1.41
Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response. J Clin Oncol (1993) 1.39
The AJCC staging proposal for cutaneous melanoma: comments by the EORTC Melanoma Group. Ann Oncol (2001) 1.38
[Thyroid metastases as cause of thyroid swelling]. Ned Tijdschr Geneeskd (1993) 1.38
Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery (1994) 1.23
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol (1997) 1.20
Treatment of ruptured hepatocellular adenoma. Br J Surg (2001) 1.20
Regulation of iron metabolism in the acute-phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients. Eur J Clin Invest (1998) 1.19
Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst (1995) 1.15
Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells. Surgery (1987) 1.15
Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer (2000) 1.14
Multicentre study of ultrasonographically guided axillary node biopsy in patients with breast cancer. Br J Surg (1999) 1.13
Differential regulation of breast tumor cell proliferation by stromal fibroblasts of various breast tissue sources. Int J Cancer (1996) 1.13
Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer (1999) 1.06
Stromal influences on breast cancer cell growth. Br J Cancer (1992) 1.03
Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int J Cancer (2000) 1.01
Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg (1996) 1.00
Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer (1996) 0.99
VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha. J Pathol (1995) 0.98
The microscopic anatomy of experimental rat CC531 colon tumour metastases: consequences for immunotherapy? Clin Exp Metastasis (2000) 0.97
Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Cancer J Sci Am (1997) 0.96
Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg (1995) 0.96
Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int J Cancer Suppl (1992) 0.94
Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan. Br J Cancer (1997) 0.93
Ultrasound-guided percutaneous transhepatic cholecystostomy for acute acalculous cholecystitis. Arch Surg (1985) 0.91
Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Recent Results Cancer Res (1998) 0.91
Loss of imprinting of IGF2 and not H19 in breast cancer, adjacent normal tissue and derived fibroblast cultures. FEBS Lett (1998) 0.91
Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approach. Eur J Surg Oncol (1996) 0.90
Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg (1999) 0.90
Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol (1999) 0.89
Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res (1999) 0.89
Ferumoxides-protamine sulfate is more effective than ferucarbotran for cell labeling: implications for clinically applicable cell tracking using MRI. Contrast Media Mol Imaging (2009) 0.89
Isolated limb perfusion in the management of patients with recurrent limb melanoma: an important but limited role. Ann Surg Oncol (2001) 0.89
Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs. Ann Surg (1998) 0.88
High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer. J Immunother (1997) 0.87
The development of novel mouse monoclonal antibodies against the CC531 rat colon adenocarcinoma. Clin Exp Metastasis (2000) 0.86
Therapeutic surgical management of palpable melanoma groin metastases: superficial or combined superficial and deep groin lymph node dissection. Ann Surg Oncol (2011) 0.86
Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res (1994) 0.86
Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg (1999) 0.85
Management of hepatocellular adenoma during pregnancy. Liver (2000) 0.85
Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg (1994) 0.85
Adenovirus-mediated interleukin 3 beta gene transfer by isolated limb perfusion inhibits growth of limb sarcoma in rats. Hum Gene Ther (2001) 0.85
A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities. Eur J Cancer (1995) 0.85
Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone. Eur J Surg Oncol (2001) 0.84
Biodistribution of lymphokine-activated killer (LAK) cells in Wag rats after hepatic-artery or jugular-vein infusion. Int J Cancer (1992) 0.83
Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg (1994) 0.83
Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage. Ann Surg Oncol (2000) 0.83
Systemic leakage during isolated limb perfusion for melanoma. Br J Surg (1993) 0.83
Controlled introduction of the sentinel node biopsy in breast cancer in a multi-centre setting: the role of a coordinator for quality control. Eur J Surg Oncol (2000) 0.82
A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats. Br J Cancer (1990) 0.82
The regulatory role of CD45 on rat NK cells in target cell lysis. J Immunol (1999) 0.82
Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin Surg Oncol (1998) 0.82
Effects of the interferon-inducer ABPP on colon cancer in rats; importance of tumor load and tumor site. Cancer Immunol Immunother (1986) 0.82
Transient induction of E-selectin expression following TNF alpha-based isolated limb perfusion in melanoma and sarcoma patients is not tumor specific. J Immunother Emphasis Tumor Immunol (1996) 0.82
Effects of isolated limb perfusion with tumour necrosis factor-alpha on the function of monocytes and T lymphocytes in patients with cancer. Eur J Clin Invest (1996) 0.82
Dynamic contrast-enhanced MRI using macromolecular contrast media for monitoring the response to isolated limb perfusion in experimental soft-tissue sarcomas. MAGMA (2004) 0.81
Assessment of the role of neutrophils on the antitumor effect of TNFalpha in an in vivo isolated limb perfusion model in sarcoma-bearing brown Norway rats. J Surg Res (1998) 0.81
Transforming growth factor beta secretion from primary breast cancer fibroblasts. Mol Cell Endocrinol (1995) 0.80
Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limb. Eur J Cancer (1993) 0.80
Is there an indication for a double perfusion schedule with melphalan for patients with recurrent melanoma of the limbs? Melanoma Res (1994) 0.80
Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives. Curr Oncol Rep (2001) 0.80
Endothelial P-selectin expression is reduced in advanced primary melanoma and melanoma metastasis. Am J Pathol (1998) 0.80
Rat interleukin-2-activated natural killer (A-NK) cell-mediated lysis is determined by the presence of CD18 on A-NK cells and the absence of major histocompatibility complex class I on target cells. Eur J Immunol (1994) 0.80
Isolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas. Ann Surg (2000) 0.80
The requirements for successful immunotherapy of intraperitoneal cancer using interleukin-2 and lymphokine-activated killer cells. Cancer (1987) 0.80
TNF-alpha has no direct in vivo metabolic effect on human muscle. Int J Cancer (1997) 0.80
Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions. Br J Cancer (2000) 0.80
The emerging role of cytokines in the treatment of advanced melanoma. For the EORTC Melanoma Cooperative Group. Oncology (2000) 0.79